Cytosorbents Reports Q1 2026 Earnings with Revenue Growth and Cost Reductions
Cytosorbents reported first-quarter earnings for 2026, showing a slight revenue increase of $8.9 million year-over-year despite challenges in the German market. The company reduced operating expenses by about 10% through workforce reductions and cost-cutting measures, leading to an improved adjusted EBITDA loss compared to last year.
Topics: cost_reduction financial_performance regulatory_progress